CN1261535A - Use of methionine composition in preparation of medicine for curin cardio-cerebral vascular diseases - Google Patents
Use of methionine composition in preparation of medicine for curin cardio-cerebral vascular diseases Download PDFInfo
- Publication number
- CN1261535A CN1261535A CN 99114631 CN99114631A CN1261535A CN 1261535 A CN1261535 A CN 1261535A CN 99114631 CN99114631 CN 99114631 CN 99114631 A CN99114631 A CN 99114631A CN 1261535 A CN1261535 A CN 1261535A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- vitamin
- methionine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The methionine composition is prepared by using methionine, choline ditartrate, nicotinamide, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid and calcium pantothenate as raw material and through compounding in certain proportion, mixing and disinfection. It is used to treat arteriosclerosis, coronary heart disease, angina pectoris, arrhythmia and other diseases.
Description
The present invention relates to the purposes of methionine composition, relate in particular to the purposes in pharmaceutical field.
Methionine composition of the present invention, it promptly is the DONGBAO GANTAI PIAN of producing by Chinese Dongbao of Tonghua Pharmaceutical limited company, it is a kind of specific medicament that is mainly used in prevention and diseases such as treatment fatty liver, acute hepatitis, chronic hepatitis and liver cirrhosis, authentication code: Ji is defended the accurate word (1996) of medicine No. 430110, and this medicine is to be made by following component:
100 parts of 100 parts of adipokinetic hormones of methionine
2 parts of 6 parts of vitamin B1s of nicotiamide
2 parts of 2 parts of vitamin Bies of vitamin B2
0.4 part in 0.67 part of folic acid of vitamin B12
3 parts of calcium pantothenates
Above-mentioned umber is weight portion.
Described methionine composition has been the commodity medicine, and is widely used in diseases such as clinical treatment fatty liver, acute hepatitis, chronic hepatitis and liver cirrhosis, finds no any toxic reaction.But Shang Weijian uses it for the report of the treatment heart, cerebrovascular disease aspect.
The object of the present invention is to provide the new purposes of methionine composition, i.e. new application in pharmacy the invention still further relates to the application of mixture in pharmaceutical field of this methionine composition and raw sangqi ginseng powder simultaneously.
Be further to understand essence of the present invention, the effect that will produce in the test of the clinical treatment heart, cerebrovascular disease with methionine composition illustrates its new purposes in pharmaceutical field below.
Proportioning by above-mentioned methionine composition takes by weighing various raw materials, with the abundant mixing and stirring of various raw materials, makes methionine composition after sterilization, sterilization.
Be used for the treatment of the clinical trial of ocular fundus arteriosclerosis and cerebral arteriosclerosis disease:
Treatment ocular fundus arteriosclerosis and cerebral arteriosclerosis case be totally 143 examples, and wherein the age minimum is 30 years old, and oldest is 83 years old.All with hyperlipidemia, wherein 125 with hypertension through lab testing for 143 patients, and 11 with diabetes.Diagnosis basis: symptom, dizziness, feeling of fullness in the head, headache, tinnitus, faintness etc.; Cerebral blood flow diagram: cerebral blood supply insufficiency; Optical fundus tremulous pulse inspection shows: the optical fundus arteria retina slightly hardens, significantly sclerosis; Electronic computer Digital Subtraction method selective brain angiography shows: the cerebral arterial stenosis that 5 patients are arranged.Therapeutic Method: oral above-mentioned methionine composition, every day 3 times, each 1.32 grams.After 30-120 days treatment, review result shows that symptom all disappears, and every inspection recovers that all 104 examples are arranged normally, treatment back transference cure, and rheoencephalogram is normal, and the optical fundus tremulous pulse transfers slight hardened 34 examples that have to by remarkable sclerosis; 5 cerebral arterial stenosis patients all recover normal.
Be used for the treatment of the hardened clinical trial of renal arteriosclerosis and artery of extremity;
Treatment renal arteriosclerosis patient is totally 73 examples, age reckling 43 years old, and the maximum 83 years old, wherein with 65 examples of hypertension, hyperlipidemia, all the other 8 examples are with diabetes.The diagnosis basis: symptom: patient has polyuria, nocturia symptom; The urine routine examination shows: albuminuria, erythrocyte, transparent or granular cast etc. are arranged; Kidney function test shows: flesh fibre, blood urea nitrogen increase; The kidney ultrasonic examination by Doppler's method shows: the kidney blood flow reduces; Electronic computer Digital Subtraction angiography shows: 23 patient's renal artery stenosis are arranged.Therapeutic Method: oral methionine composition, every day 3 times, each 1.32 grams.Through after 22-120 days the treatment, check has 68 routine transference cures, and every inspection all recovers normally, and Most patients took medicine back about 15 days, and the nocturia symptom is complete obiteration.
Treatment artery of extremity sclerosis patient 38 examples, all patients are all with numb limbs and tense tendons, send out cool symptom, 16 examples are wherein arranged also with intermittent claudication, and foot is weakened by arteriopalmus or disappears, and after said medicine was treated, disease all disappeared.
Be used for the treatment of the arteriosclerotic clinical trial of diabetic:
The treatment type ii diabetes is with the patient of hyperlipidemia and in various degree the heart, brain, kidney, ocular fundus arteriosclerosis totally 16 examples.Wherein the age minimum is 43 years old, and oldest is 79 years old.Therapeutic Method: in the time of oral as stated above methionine composition, also to take hypoglycemic medicine, treat that blood glucose is turned out cloudy after, change the diabetes pill that the clothes Guangzhou No.1 Chinese Pharmacy Factory is produced, each 5, every day 3 times.Through after 60-120 days the treatment, the hardened tremulous pulse of each corresponding organ is checked discovery all recover normal.
Be used for the treatment of the clinical trial of coronary heart disease, angina pectoris and various arrhythmias:
Treatment arrhythmia and because the coronary atherosclerosis angina pectoris, the patients with coronary heart disease that cause, totally 86 examples, wherein the age minimum is 38 years old, the maximum is 79 years old.All with hyperlipidemia, mainly be that LDL raises among the 86 routine patients, with hyperpietic's 50 examples, arrhythmia person 18 examples, companion's glycosuria patient 6 examples.Diagnosis basis: symptom: more than uncomfortable in chest, nervous, cardiopalmus, retrosternal pain, the dream etc.; 37 patients show through the color doppler ultrasonography kinetocardiography: coronary artery blood flow reduces; 12 patients show that through nuclear magnetic resonance tomographic imaging (MRI-CT) inspection aorta and crown intra-arterial have atherosclerotic plaque; Ordinary electrocardiogram and dynamic ecg recordings examination show, coronary insufficiency, myocardial ischemia, arrhythmia etc.; Coronarography shows, coronary stricture.Therapeutic Method: oral methionine composition, every day 3 times, each 1.32 grams, after 40-120 days treatment, checking has every check result of 78 patients all to recover normal.The patient of 2 routine atrial fibrillation hearts rate wherein, heart rate recovers normal substantially after treating; 17 examples have the patient of symptoms such as back ventricle premature beat, bradycardia, tachycardia, atrioventricular block all to cure.Wherein 11 examples are with the patient of uncomfortable in chest, nervous, tachypnea, lower limbs edema and slight symptoms of heart failure, above-mentioned disease complete obiteration after treating.
Below will be further with methionine composition and the mixed medicine that gets of raw sangqi ginseng powder, the effect that produces in the test of the aforementioned various diseases of clinical treatment illustrates its new purposes in pharmaceutical field.
The raw sangqi ginseng powder is with the distinctive wild drug resource in Yunnan---the dry root of panax araliaceae plant through the powdered drug that pulverizing makes, has effects such as diffusing congestion, subduing swelling and relieving pain.
Methionine composition is during with raw sangqi ginseng powder mixing pharmacy, and mixed proportion is a methionine composition: raw sangqi ginseng powder=33: 75-125.
Get methionine composition 132 grams, pulverize the back and add 300 gram raw sangqi ginseng powder, and stand-by after mixing, stir, sterilize, sterilizing.
With aforementioned diseases such as the medicine that methionine composition and raw sangqi ginseng powder make, treatment ocular fundus arteriosclerosis, cerebral arteriosclerosis, renal arteriosclerosises.Therapeutic Method: the medicine that oral methionine composition and raw sangqi ginseng powder make, every day 3 times, each 4.32-6.32 gram.
Result of the test shows that the medicine that methionine composition and raw sangqi ginseng powder make all has excellent curative to above-mentioned various diseases.During clinical treatment, follow-up investigations are also found, take the patient of methionine composition separately, at the initial stage of taking medicine, original dizziness, headache, blurring of vision, disease such as uncomfortable in chest, nervous have the phenomenon that increases the weight of, and the patient of the hybrid medicine of clothes methionine composition and raw sangqi ginseng powder, above-mentioned phenomenon does not all occur.
Above result shows that the present invention has following advantage:
1, the present invention excavates out the new medical application of known drug-methionine composition, has opened up a new medical applications field.
2, in the each component of methionine composition, methionine can synthesize in liver in the process of choline provides methyl, promotes the synthetic of choline, choline with accumulate in the liver and intravital fat effect, become the lecithin that is easy to absorb, so there is the effect of fat; Adipokinetic hormone is the ingredient of lecithin, can promote lipid metabolism in the liver, makes it transfer lecithin to, and then synthetic fat albumen enters blood, thereby can reduce fat accumulating in liver; Nicotinoyl ammonia is nadide, coenzyme II constituent, plays hydrogenation, dehydrogenation in biological oxidation, can be used for improving the cardiac muscle conduction and improves sinus node function; Calcium pantothenate can participate in constituting coenzyme A, can promote sugar, fat and proteinic metabolism; Vitamin B complex provides the precursor substance of methyl, is the important component of synthetic choline, has the fat of becoming effect.In above-mentioned clinical trial, find, each composition in the methionine composition not only just participates in lipid metabolism in the liver, also participate in total body fat and blood lipid metabolism, wherein vitamin B complex and folic acid can also reduce the content of the homocysteine in the blood, to increase the atherosclerosis of initiation because of homocysteine in the blood, coronary heart disease, has excellent curative, add that the raw sangqi ginseng powder has activating blood circulation to dissipate blood stasis, reduce the blood fat in the serum, the effect of blood viscosity lowering, effectively reduction of patient is because of taking the methionine composition initial stage, the fat that gets off because of metabolism on blood vessel wall enters the blood viscosity that blood causes and increases, the phenomenon that original disease temporarily increases the weight of, thereby make it can effectively remove the interior thrombosis of large artery trunks, atherosclerotic plaque, softening arteries, blood viscosity lowering and flow resistance thereof, alleviate cardiac afterload, strengthen the heart, brain, the blood supply of vitals such as kidney.
3, the present invention shows through clinical trial, the hybrid medicine that disconnected acid composition of methionine combination and egg ammonia and raw sangqi ginseng powder make to symptoms such as arteriosclerosis, coronary heart disease, angina pectoris and various arrhythmias, takes effect rapidly, evident in efficacy, have a good application prospect.
Embodiment 1
Take by weighing raw material (unit: restrain) by following proportioning:
Methionine 100 adipokinetic hormones 100
Nicotiamide 6 vitamin B1s 2
Vitamin B2 2 vitamin Bies 2
Vitamin B12 0.67 folic acid 0.4
Calcium pantothenate 3
With the abundant mixing and stirring of various raw materials, after sterilization, sterilization, make methionine composition.
Embodiment 2
Get methionine composition 132 grams, pulverize the back and add 300 gram raw sangqi ginseng powder, after mixing, stir, sterilize, sterilizing, make product.The medicine that this prescription makes is taken 3 every day, each 4.32 grams.
Embodiment 3
Get methionine composition 132 grams, pulverize the back and add 500 gram raw sangqi ginseng powder, after mixing, stir, sterilize, sterilizing, make product.The product that this prescription makes is obeyed 3 every day, each 6.32 grams.
Embodiment 4
Get methionine composition 132 grams, pulverize the back and add 400 gram raw sangqi ginseng powder, after mixing, stir, sterilize, sterilizing, make product.By the product that this prescription makes, obey each 5.32 grams every day 3 times.
Claims (6)
1, the application of following methionine composition in the medicine of the preparation treatment heart, cerebrovascular disease,
100 parts of 100 parts of adipokinetic hormones of methionine
2 parts of 6 parts of vitamin B1s of nicotiamide
2 parts of 22 parts of vitamin Bies of vitamin B
0.4 part in 120.67 parts of folic acid of vitamin B
3 parts of calcium pantothenates
Above-mentioned umber is weight portion.
2, the application of the described pharmaceutical composition of claim 1 in the arteriosclerotic medicine of preparation treatment.
3, the application in the arteriosclerotic medicine that the described pharmaceutical composition of claim 1 is treated coronary atherosclerosis, cerebral arteriosclerosis, ocular fundus arteriosclerosis, kidney arteriosclerosis in preparation, artery of extremity hardens and cause because of diabetes.
4, the application of the described pharmaceutical composition of claim 1 in preparation treatment coronary heart disease, anginal medicine.
5, the application of the described pharmaceutical composition of claim 1 in the medicine of preparation treatment arrhythmia.
6, described pharmaceutical composition of claim 1 and the raw sangqi ginseng powder application in the medicine of disease described in the preparation treatment claim 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB99114631XA CN1135973C (en) | 1999-01-18 | 1999-01-18 | Use of methionine composition in preparation of medicine for curin cardio-cerebral vascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB99114631XA CN1135973C (en) | 1999-01-18 | 1999-01-18 | Use of methionine composition in preparation of medicine for curin cardio-cerebral vascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1261535A true CN1261535A (en) | 2000-08-02 |
| CN1135973C CN1135973C (en) | 2004-01-28 |
Family
ID=5277688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB99114631XA Expired - Fee Related CN1135973C (en) | 1999-01-18 | 1999-01-18 | Use of methionine composition in preparation of medicine for curin cardio-cerebral vascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1135973C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100349578C (en) * | 2005-04-29 | 2007-11-21 | 朱舜时 | Medicine composition for treating atrophic gastritis |
| CN1853654B (en) * | 2005-04-29 | 2010-05-26 | 浙江山下湖珍珠集团股份有限公司 | Oral preparation containing pearl and vitamine |
| WO2019124483A1 (en) * | 2017-12-21 | 2019-06-27 | 国立大学法人大阪大学 | Agent for treatment of nervous system disease |
-
1999
- 1999-01-18 CN CNB99114631XA patent/CN1135973C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100349578C (en) * | 2005-04-29 | 2007-11-21 | 朱舜时 | Medicine composition for treating atrophic gastritis |
| CN1853654B (en) * | 2005-04-29 | 2010-05-26 | 浙江山下湖珍珠集团股份有限公司 | Oral preparation containing pearl and vitamine |
| WO2019124483A1 (en) * | 2017-12-21 | 2019-06-27 | 国立大学法人大阪大学 | Agent for treatment of nervous system disease |
| JPWO2019124483A1 (en) * | 2017-12-21 | 2019-12-26 | 国立大学法人大阪大学 | Nervous system therapeutic agent |
| JP2020075931A (en) * | 2017-12-21 | 2020-05-21 | 国立大学法人大阪大学 | Nervous system disease therapeutic agent |
| JP2020117529A (en) * | 2017-12-21 | 2020-08-06 | 国立大学法人大阪大学 | Agent for treatment of nervous system disease |
| US11369626B2 (en) | 2017-12-21 | 2022-06-28 | Osaka University | Therapeutic agent for nervous system disease |
| TWI798320B (en) * | 2017-12-21 | 2023-04-11 | 國立大學法人大阪大學 | Therapeutic agent for nervous system disease |
| US11679122B2 (en) | 2017-12-21 | 2023-06-20 | Osaka University | Therapeutic agent for nervous system disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1135973C (en) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maseri et al. | Coronary vasospasm in angina pectoris | |
| Hunter et al. | Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication | |
| Greenway et al. | A clinical trial testing the safety and efficacy of a standardized Eucommia ulmoides Oliver bark extract to treat hypertension | |
| RU2482865C2 (en) | Pharmaceutical composition for treating cardiomyopathy | |
| CN111195340B (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method and application thereof | |
| CN101903033A (en) | The purposes of the extract of making by Folium Ginkgo | |
| US20080241273A1 (en) | Mastic gum composition for use as a dietary supplement in humans and animals | |
| Adnitt | Hypoglycemic action of monoamineoxidase inhibitors (MAOI'S) | |
| CN1135973C (en) | Use of methionine composition in preparation of medicine for curin cardio-cerebral vascular diseases | |
| RU2029474C1 (en) | Chewing gum | |
| Mastaglia et al. | Mitochondrial myopathy with cardiomyopathy, lactic acidosis and response to prednisone and thiamine | |
| CN100518751C (en) | Medicine for preventing and treating cardiovascular and cerebrovascular diseases by increasing hypoxia-resistant ability and its preparing method | |
| Levy et al. | Pyridoxine deficiency in congestive heart failure | |
| Baird et al. | Absorption of slow-release iron and effects of ascorbic acid in normal subjects and after partial gastrectomy | |
| CN102233028B (en) | Composite preparation for treating osteoporosis | |
| RU2485965C2 (en) | Compartment-specific dual combination of herbal extracts of ginkgo biloba and ginseng | |
| Lemieux et al. | Treatment of arterial hypertension with tienilic acid, a new diuretic with uricosuric properties. | |
| JP2002522507A (en) | Treatment of disease states | |
| CN1202842C (en) | Medicine composition for preventing and treating thrombosis and relative disease | |
| CN102823799A (en) | Health care food capable of improving bodily immunity and supplementing vitamin | |
| CN107737108A (en) | A kind of combination of oral medication for treating Pathogenesis of Post-infarction Ventricular Remodeling | |
| RU2201179C2 (en) | Method for treating diabetic retinopathies | |
| CN100490824C (en) | Medicinal composition for treating blood vessel kind disease, its preparation process and its use | |
| Kopera | Cardiac effects of mianserin: results of clinical pharmacological investigations | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |